|
|
 |
|
At Ronak healthcare, we constantly try and improve our services to serve you better. If you have any suggestions / comments that you would like to share with us, do take a minute to fill in the feedback form.
|
|
The production Area has sufficient space planned for different manufacturing activities. The production area has a separate entrance to different sections, such as tablets & capsules (general), liquid orals (general), small volume Liquid Parenterals (general), ointments / cream manufacturing. The separate building block is created for manufacturing of beta-lactum range of products such as sterile dry powder injectables, dry syrup, tablets & capsules.
 More about our Manufacturing Strength
Our scientists are working hard to discover new ways of treating illness and disease. In addition to their wide-ranging talents, we use the resources of a company devoted to the application of science to improve the quality of life.
we need to be determined and innovative to develop our molecules into medicines as fast as possible.
Using the most modern technology, we can maintain a healthy product pipeline which ensures a flow of new products to people around the world.
We are one of the largest collaborators in industry and work with academic institutions, governments, and other pharmaceutical and biotechnology companies. We believe that the strength of our combined efforts will help people live healthier and happier lives.
More about our Research Strength
Like all innovative pharmaceutical companies, we carry out a series of clinical trials to test each investigational drug for the potential to become a new medicine.
Phase I trials typically involve healthy volunteers. These trials study the safety of the drug and its interaction with the body, for example, its concentration and duration in the blood following various doses, and begin to answer such questions as whether the drug inhibits or amplifies the effects of other medicines that might be taken at the same time.
Phase II studies enrol patients with the illness an investigational drug is designed to treat. These trials evaluate whether the drug shows favourable effects in treating an illness and seek to determine the proper dose. They provide an opportunity to explore the therapeutic potential of the drug in what may be quite different illnesses. The evaluation of safety continues.
If Phase II results have been encouraging, Phase III trials, the largest part of a clinical-development program, go forward. Phase III trials are designed to provide the substantial evidence of efficacy and safety required, in addition to data from earlier-phase trials, before regulatory agencies will approve the investigational drug as a medicine and allow it to be marketed.
Trials of a medicine may continue even after it has been approved for marketing. Known as Phase IV trials, they may further evaluate the effect of the medicine for the approved use, assess other potential uses, or yield additional safety data. Regulatory agencies may require these trials to address specific questions.
Given the exploratory nature of clinical development, investigators often need to conduct trials of varying designs to determine the potential of an investigational drug and its best use. Rarely does any one trial enable a full understanding.
The prescribing information ultimately approved by those agencies, following their own authoritative, cross-study analyses, directs the appropriate use of the medicine.
Although pharmaceutical companies design and take responsibility for the trials they sponsor, any clinical-development program ultimately depends on the commitment of physician-investigators and the patients they enrol in the settings of clinics and hospitals. A new medicine, or new use of a medicine, is the result of a collaborative, often international effort.
|
|